What is the appropriate management for a patient with severe acute liver injury and coagulopathy indicated by hyperferritinemia, markedly elevated vitamin B12, high direct bilirubin, elevated AST and ALT, hypoalbuminemia, prolonged prothrombin time/international normalized ratio, hypocalcemia, and low magnesium?

Immediate Management of Severe Acute Liver Failure with Coagulopathy

This patient requires immediate ICU-level care with systematic N-acetylcysteine administration regardless of etiology, urgent etiological workup, early transplant center contact, and avoidance of routine coagulation correction unless actively bleeding. 1

Critical Initial Actions

Your patient meets criteria for severe acute liver failure (PT ratio < 50%, INR 2.2) with significant coagulopathy and multi-organ dysfunction evidenced by hypoalbuminemia (2.2 g/dL), hypocalcemia (7.7 mg/dL), and hypomagnesemia (1.4 mg/dL). The markedly elevated ferritin (1142 ng/mL) and B12 (2186 pg/mL) reflect hepatocellular necrosis and release of intracellular contents rather than primary iron overload. 2

Immediate Therapeutic Interventions

Start N-acetylcysteine immediately without waiting for acetaminophen levels - this is a Grade 1+ strong recommendation for all ALF patients regardless of suspected etiology. 1 The evidence shows improved 21-day survival (48% vs 25%, p=0.037) and reduced progression to grade III-IV encephalopathy even in non-acetaminophen ALF. 1

Contact a liver transplant center now - this is mandatory for any patient with PT ratio < 50%. 1 Early transfer discussion is critical as your patient's INR 2.2 with encephalopathy (if present) would meet transplant evaluation criteria.

Essential Diagnostic Workup

Perform these investigations urgently to guide specific therapy and prognosis: 1

• Serum acetaminophen level (most common cause, 22% of transplant cases)
• Viral serologies: Hepatitis A IgM, Hepatitis B surface antigen and core IgM antibody
• Urine toxicology screen: amphetamines, cocaine
• Hepatic Doppler ultrasound: exclude Budd-Chiari syndrome, assess vessel patency, rule out chronic liver disease
• Echocardiography: especially given AST:ALT ratio > 2 (176:89), consider ischemic hepatitis
• Arterial blood gas with lactate: lactate > 3.5 mmol/L at 4 hours or > 3.0 mmol/L at 12 hours indicates poor prognosis
• Arterial ammonia level: threshold > 100 μmol/L associated with encephalopathy risk
• Factor V level: < 20% indicates poor prognosis 1

The AST:ALT ratio of approximately 2:1 with relatively modest transaminase elevation (AST 176, ALT 89) suggests either ischemic hepatitis, alcoholic hepatitis, or late-stage acute injury. This differs from acetaminophen toxicity which typically shows AST/ALT in thousands. 1

Coagulation Management - Critical Pitfall

Do NOT routinely correct the INR 2.2 with fresh frozen plasma or clotting factors. 1 This is a strong recommendation that contradicts traditional practice. Here's why:

• ALF represents a state of "rebalanced hemostasis" - both pro-coagulant and anticoagulant factors are reduced proportionally 3, 4
• PT/INR does not predict bleeding risk in liver failure 3, 5
• Routine FFP transfusion provides minimal benefit and increases volume overload risk 3
• Only correct coagulation if active bleeding occurs 1

The elevated direct bilirubin (5.0 mg/dL) with total bilirubin (6.8 mg/dL) indicates predominantly conjugated hyperbilirubinemia, consistent with hepatocellular dysfunction rather than hemolysis.

Metabolic and Electrolyte Management

Address these abnormalities systematically: 6

Hypocalcemia (7.7 mg/dL):

• Correct with calcium supplementation
• Monitor ionized calcium levels
• May require repeated dosing throughout hospital course

Hypomagnesemia (1.4 mg/dL):

• Replete magnesium aggressively
• Expect need for repeated supplementation 6

Hypoalbuminemia (2.2 g/dL):

• Reflects synthetic dysfunction
• Consider albumin infusion for hemodynamic support if needed
• Do not use solely to "correct" albumin level

Monitor glucose every 2 hours - hypoglycemia is common and symptoms may be masked by encephalopathy. Use continuous glucose infusions as needed. 1, 6

Maintain sodium 140-145 mmol/L to prevent cerebral edema risk. 1

Encephalopathy Surveillance and Management

Monitor encephalopathy grade frequently as this determines prognosis and transplant urgency: 1

• Grade 1-2 encephalopathy: 52% short-term survival
• Grade 3-4 encephalopathy: 33% short-term survival, 38-81% risk of cerebral edema

If encephalopathy develops:

• Intubate if Glasgow Coma Scale < 8 1
• Minimize sedation depth
• Do NOT use lactulose or rifaximin in ALF - these are contraindicated (only for chronic liver disease/ACLF) 1
• Consider plasma exchange if hyperammonemia develops (conditional recommendation) 7

Hemodynamic and Organ Support

Cardiovascular management: 1, 6

• Assess volume status with echocardiography
• Use crystalloid fluids as first-line for volume expansion
• Norepinephrine for refractory hypotension (maintain MAP 50-60 mmHg)
• Avoid vasopressin

Renal support:

• Use continuous renal replacement therapy if dialysis needed (not intermittent) 6

Infection surveillance:

• Empirical broad-spectrum antibiotics if signs of SIRS or worsening encephalopathy 1
• Stress ulcer prophylaxis 1

Prognostic Indicators for Transplant Evaluation

Your patient should be evaluated against King's College Criteria and other poor prognostic factors: 1

Poor prognosis indicators:

• pH < 7.3
• PT > 100 seconds (your patient: PT 24.7 seconds - monitor trend)
• Creatinine > 300 μmol/L
• Grade 3-4 encephalopathy
• Lactate > 3.5 mmol/L at 4 hours
• Ammonia > 100 μmol/L
• Bilirubin > 140-200 μmol/L (your patient: ~116 μmol/L)

The etiology significantly affects transplant-free survival: acetaminophen/hepatitis A/pregnancy have 50% survival, while hepatitis B/autoimmune/Wilson's disease have < 25% survival without transplant. 1

What NOT to Do

Critical contraindications in ALF management: 1

• No benzodiazepines or psychotropic drugs (including metoclopramide)
• No lactulose or rifaximin (these are for chronic liver disease only)
• No nephrotoxic drugs including NSAIDs
• No routine coagulation correction unless active bleeding
• No protein restriction - provide 60g/day protein 6

Monitoring Algorithm

Establish this surveillance protocol:

1. Neurological: Encephalopathy grade every 4-6 hours
2. Metabolic: Glucose every 2 hours, electrolytes every 6-12 hours
3. Coagulation: Daily PT/INR, Factor V if available
4. Hemodynamic: Continuous monitoring if unstable
5. Infection: Temperature, white count, cultures if fever

The combination of severe synthetic dysfunction (albumin 2.2, INR 2.2), cholestasis (direct bilirubin 5.0), and hepatocellular injury (AST 176, ALT 89) with metabolic derangements constitutes a medical emergency requiring intensive care unit management with immediate transplant center involvement.